MDGL
Price
$197.36
Change
+$6.42 (+3.36%)
Updated
Nov 29, 6:59 PM EST
85 days until earnings call
MNKD
Price
$3.54
Change
+$0.04 (+1.14%)
Updated
Nov 29, 6:59 PM EST
90 days until earnings call
Ad is loading...

Analysis and predictions MDGL vs MNKD

Header iconMDGL vs MNKD Comparison
Open Charts MDGL vs MNKDBanner chart's image
Madrigal Pharmaceuticals
Price$197.36
Change+$6.42 (+3.36%)
Volume$155.95K
CapitalizationN/A
MannKind
Price$3.54
Change+$0.04 (+1.14%)
Volume$1.07M
CapitalizationN/A
View a ticker or compare two or three
MDGL vs MNKD Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
MDGL vs. MNKD commentary
Nov 29, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Buy and MNKD is a Sell.

COMPARISON
Comparison
Nov 29, 2023
Stock price -- (MDGL: $190.94 vs. MNKD: $3.50)
Brand notoriety: MDGL and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 51% vs. MNKD: 84%
Market capitalization -- MDGL: $3.9B vs. MNKD: $948.9M
MDGL [@Biotechnology] is valued at $3.9B. MNKD’s [@Biotechnology] market capitalization is $948.9M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 0 FA rating(s) are green whileMNKD’s FA Score has 2 green FA rating(s).

  • MDGL’s FA Score: 0 green, 5 red.
  • MNKD’s FA Score: 2 green, 3 red.
According to our system of comparison, MNKD is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 6 TA indicator(s) are bullish while MNKD’s TA Score has 4 bullish TA indicator(s).

  • MDGL’s TA Score: 6 bullish, 4 bearish.
  • MNKD’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than MNKD.

Price Growth

MDGL (@Biotechnology) experienced а +1.33% price change this week, while MNKD (@Biotechnology) price change was -5.66% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.60%. For the same industry, the average monthly price growth was +37.65%, and the average quarterly price growth was +9.10%.

Reported Earning Dates

MDGL is expected to report earnings on Feb 22, 2024.

MNKD is expected to report earnings on Feb 27, 2024.

Industries' Descriptions

@Biotechnology (+4.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for MDGL with price predictions.
OPEN
A.I.dvisor published
a Summary for MNKD with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MDGL($3.9B) has a higher market cap than MNKD($949M). MNKD (-33.586) and MDGL (-34.215) have similar YTD gains . MNKD has higher annual earnings (EBITDA): 2.24M vs. MDGL (-336.4M). MDGL has more cash in the bank: 232M vs. MNKD (141M). MDGL has less debt than MNKD: MDGL (117M) vs MNKD (278M). MNKD has higher revenues than MDGL: MNKD (177M) vs MDGL (0).
MDGLMNKDMDGL / MNKD
Capitalization3.9B949M410%
EBITDA-336.4M2.24M-14,998%
Gain YTD-34.215-33.586102%
P/E RatioN/AN/A-
Revenue0177M-
Total Cash232M141M165%
Total Debt117M278M42%
FUNDAMENTALS RATINGS
MDGL vs MNKD: Fundamental Ratings
MDGL
MNKD
OUTLOOK RATING
1..100
2857
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
4
Undervalued
PROFIT vs RISK RATING
1..100
10049
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3575
P/E GROWTH RATING
1..100
10026
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNKD's Valuation (4) in the Biotechnology industry is significantly better than the same rating for MDGL (96) in the Pharmaceuticals Other industry. This means that MNKD’s stock grew significantly faster than MDGL’s over the last 12 months.

MNKD's Profit vs Risk Rating (49) in the Biotechnology industry is somewhat better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that MNKD’s stock grew somewhat faster than MDGL’s over the last 12 months.

MNKD's SMR Rating (100) in the Biotechnology industry is in the same range as MDGL (100) in the Pharmaceuticals Other industry. This means that MNKD’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Price Growth Rating (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for MNKD (75) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than MNKD’s over the last 12 months.

MNKD's P/E Growth Rating (26) in the Biotechnology industry is significantly better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that MNKD’s stock grew significantly faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLMNKD
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 15 days ago
86%
Declines
ODDS (%)
Bearish Trend 21 days ago
81%
Bearish Trend 2 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
76%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CXE3.350.03
+0.90%
MFS High Income Municipal Trust
ECLN23.770.14
+0.61%
First Trust EIP Carbon Impact ETF
STLV25.67N/A
N/A
iShares Factors US Value Style ETF
XAR126.11-0.26
-0.21%
SPDR® S&P Aerospace & Defense ETF
QID11.87-0.06
-0.50%
ProShares UltraShort QQQ